 | • レポートコード：QY20ST-06903 • 出版社/出版日：QYResearch / 2020年9月15日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥560,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥840,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,120,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、世界の卵巣がん治療薬市場について種類別（アルキル化剤、有糸分裂阻害剤、抗精神病薬、抗腸炎薬、VEGF / VEGFR阻害剤、PARP阻害剤、抗腫瘍薬、その他）、用途別（病院薬局、ドラッグストア、オンライン薬局、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・卵巣がん治療薬市場の概要 ・世界の主要地域別卵巣がん治療薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の卵巣がん治療薬市場規模2015-2026：種類別（アルキル化剤、有糸分裂阻害剤、抗精神病薬、抗腸炎薬、VEGF / VEGFR阻害剤、PARP阻害剤、抗腫瘍薬、その他） ・世界の卵巣がん治療薬市場規模2015-2026：用途別（病院薬局、ドラッグストア、オンライン薬局、その他） ・卵巣がん治療薬の北米市場規模2015-2020 ・卵巣がん治療薬のヨーロッパ市場規模2015-2020 ・卵巣がん治療薬の中国市場規模2015-2020 ・卵巣がん治療薬の日本市場規模2015-2020 ・卵巣がん治療薬の東南アジア市場規模2015-2020 ・卵巣がん治療薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・卵巣がん治療薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・卵巣がん治療薬の市場動向・機会・課題 ・調査の結論 |
Ovarian cancer is regarded as one of the most common types of cancer among women. It accounts for more deaths than any other cancer of the female reproductive system, while it ranks 5th in overall women deaths due to cancer. This type of cancer is rarely diagnosed at an early stage, making treatment at an advanced stage difficult.
Market Analysis and Insights: Global Ovarian Cancer Drugs Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ovarian Cancer Drugs market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Ovarian Cancer Drugs industry.
Based on our recent survey, we have several different scenarios about the Ovarian Cancer Drugs YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Ovarian Cancer Drugs will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
Global Ovarian Cancer Drugs Scope and Market Size
The global Ovarian Cancer Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Ovarian Cancer Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Ovarian Cancer Drugs market is segmented into
Alkylating Agents
Mitotic Inhibitors
Antirheumatics
Antipsoriatics
VEGF/VEGFR Inhibitors
PARP Inhibitors
Antineoplastics
Others
Segment by Application, the Ovarian Cancer Drugs market is segmented into
Hospital Pharmacies
Drug Stores
Online Pharmacies
Others
The Ovarian Cancer Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Ovarian Cancer Drugs market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Ovarian Cancer Drugs Market Share Analysis
Ovarian Cancer Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Ovarian Cancer Drugs business, the date to enter into the Ovarian Cancer Drugs market, Ovarian Cancer Drugs product introduction, recent developments, etc.
The major vendors covered:
Allergan plc
Pfizer, Inc.
Merck KGaA
AstraZeneca
F. Hoffmann-La Roche AG
Johnson & Johnson
Syndax Pharmaceuticals, Inc.
Clovis Oncology
1 Ovarian Cancer Drugs Market Overview
1.1 Ovarian Cancer Drugs Product Scope
1.2 Ovarian Cancer Drugs Segment by Type
1.2.1 Global Ovarian Cancer Drugs Sales by Type (2020-2026)
1.2.2 Alkylating Agents
1.2.3 Mitotic Inhibitors
1.2.4 Antirheumatics
1.2.5 Antipsoriatics
1.2.6 VEGF/VEGFR Inhibitors
1.2.7 PARP Inhibitors
1.2.8 Antineoplastics
1.2.9 Others
1.3 Ovarian Cancer Drugs Segment by Application
1.3.1 Global Ovarian Cancer Drugs Sales Comparison by Application (2020-2026)
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Ovarian Cancer Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Ovarian Cancer Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Ovarian Cancer Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Ovarian Cancer Drugs Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Ovarian Cancer Drugs Industry Impact
1.5.1 How the Covid-19 is Affecting the Ovarian Cancer Drugs Industry
1.5.1.1 Ovarian Cancer Drugs Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Ovarian Cancer Drugs Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Ovarian Cancer Drugs Players to Combat Covid-19 Impact
2 Ovarian Cancer Drugs Estimate and Forecast by Region
2.1 Global Ovarian Cancer Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Ovarian Cancer Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Ovarian Cancer Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Ovarian Cancer Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Ovarian Cancer Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Ovarian Cancer Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Ovarian Cancer Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Ovarian Cancer Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Ovarian Cancer Drugs Estimates and Projections (2015-2026)
2.4.3 China Ovarian Cancer Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Ovarian Cancer Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Ovarian Cancer Drugs Estimates and Projections (2015-2026)
2.4.6 India Ovarian Cancer Drugs Estimates and Projections (2015-2026)
3 Global Ovarian Cancer Drugs Competition Landscape by Players
3.1 Global Top Ovarian Cancer Drugs Players by Sales (2015-2020)
3.2 Global Top Ovarian Cancer Drugs Players by Revenue (2015-2020)
3.3 Global Ovarian Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ovarian Cancer Drugs as of 2019)
3.4 Global Ovarian Cancer Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Ovarian Cancer Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Ovarian Cancer Drugs Players (Opinion Leaders)
4 Global Ovarian Cancer Drugs Market Size by Type
4.1 Global Ovarian Cancer Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Ovarian Cancer Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Ovarian Cancer Drugs Price by Type (2014-2020)
4.2 Global Ovarian Cancer Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Ovarian Cancer Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Ovarian Cancer Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Ovarian Cancer Drugs Price Forecast by Type (2021-2026)
5 Global Ovarian Cancer Drugs Market Size by Application
5.1 Global Ovarian Cancer Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Ovarian Cancer Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Ovarian Cancer Drugs Price by Application (2015-2020)
5.2 Global Ovarian Cancer Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Ovarian Cancer Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Ovarian Cancer Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Ovarian Cancer Drugs Price Forecast by Application (2021-2026)
3 North America Ovarian Cancer Drugs Market Facts & Figures
3.2 North America Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
3.3 North America Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
3.4 North America Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
4 Europe Ovarian Cancer Drugs Market Facts & Figures
4.2 Europe Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
4.3 Europe Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
4.4 Europe Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
5 China Ovarian Cancer Drugs Market Facts & Figures
5.2 China Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
5.3 China Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
5.4 China Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
6 Japan Ovarian Cancer Drugs Market Facts & Figures
6.2 Japan Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
6.3 Japan Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
6.4 Japan Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
7 Southeast Asia Ovarian Cancer Drugs Market Facts & Figures
7.2 Southeast Asia Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
8 India Ovarian Cancer Drugs Market Facts & Figures
8.2 India Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
8.3 India Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
8.4 India Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Ovarian Cancer Drugs Business
12.1 Allergan plc
12.1.1 Allergan plc Ovarian Cancer Drugs Corporation Information
12.1.2 Allergan plc Ovarian Cancer Drugs Business Overview and Total Revenue
12.1.3 Allergan plc Ovarian Cancer Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Allergan plc Ovarian Cancer Drugs Products Offered
12.1.5 Allergan plc Recent Development
12.2 Pfizer, Inc.
12.2.1 Pfizer, Inc. Ovarian Cancer Drugs Corporation Information
12.2.2 Pfizer, Inc. Ovarian Cancer Drugs Business Overview and Total Revenue
12.2.3 Pfizer, Inc. Ovarian Cancer Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Pfizer, Inc. Ovarian Cancer Drugs Products Offered
12.2.5 Pfizer, Inc. Recent Development
12.3 Merck KGaA
12.3.1 Merck KGaA Ovarian Cancer Drugs Corporation Information
12.3.2 Merck KGaA Ovarian Cancer Drugs Business Overview and Total Revenue
12.3.3 Merck KGaA Ovarian Cancer Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Merck KGaA Ovarian Cancer Drugs Products Offered
12.3.5 Merck KGaA Recent Development
12.4 AstraZeneca
12.4.1 AstraZeneca Ovarian Cancer Drugs Corporation Information
12.4.2 AstraZeneca Ovarian Cancer Drugs Business Overview and Total Revenue
12.4.3 AstraZeneca Ovarian Cancer Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 AstraZeneca Ovarian Cancer Drugs Products Offered
12.4.5 AstraZeneca Recent Development
12.5 F. Hoffmann-La Roche AG
12.5.1 F. Hoffmann-La Roche AG Ovarian Cancer Drugs Corporation Information
12.5.2 F. Hoffmann-La Roche AG Ovarian Cancer Drugs Business Overview and Total Revenue
12.5.3 F. Hoffmann-La Roche AG Ovarian Cancer Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 F. Hoffmann-La Roche AG Ovarian Cancer Drugs Products Offered
12.5.5 F. Hoffmann-La Roche AG Recent Development
12.6 Johnson & Johnson
12.6.1 Johnson & Johnson Ovarian Cancer Drugs Corporation Information
12.6.2 Johnson & Johnson Ovarian Cancer Drugs Business Overview and Total Revenue
12.6.3 Johnson & Johnson Ovarian Cancer Drugs Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Johnson & Johnson Ovarian Cancer Drugs Products Offered
12.6.5 Johnson & Johnson Recent Development
12.7 Syndax Pharmaceuticals, Inc.
12.7.1 Syndax Pharmaceuticals, Inc. Ovarian Cancer Drugs Corporation Information
12.7.2 Syndax Pharmaceuticals, Inc. Ovarian Cancer Drugs Business Overview and Total Revenue
12.7.3 Syndax Pharmaceuticals, Inc. Ovarian Cancer Drugs Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Syndax Pharmaceuticals, Inc. Ovarian Cancer Drugs Products Offered
12.7.5 Syndax Pharmaceuticals, Inc. Recent Development
12.8 Clovis Oncology
12.8.1 Clovis Oncology Ovarian Cancer Drugs Corporation Information
12.8.2 Clovis Oncology Ovarian Cancer Drugs Business Overview and Total Revenue
12.8.3 Clovis Oncology Ovarian Cancer Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Clovis Oncology Ovarian Cancer Drugs Products Offered
12.8.5 Clovis Oncology Recent Development
13 Ovarian Cancer Drugs Manufacturing Cost Analysis
13.1 Ovarian Cancer Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Ovarian Cancer Drugs
13.4 Ovarian Cancer Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Ovarian Cancer Drugs Distributors List
14.3 Ovarian Cancer Drugs Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Ovarian Cancer Drugs Sales (K Units) Growth Rate by Type (2020-2026)
Table 2. Global Ovarian Cancer Drugs Sales (K Units) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Ovarian Cancer Drugs Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Ovarian Cancer Drugs Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Ovarian Cancer Drugs Players to Combat Covid-19 Impact
Table 8. Global Market Ovarian Cancer Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Ovarian Cancer Drugs Sales (K Units) by Region (2015-2020)
Table 10. Global Ovarian Cancer Drugs Sales Market Share by Region (2015-2020)
Table 11. Global Ovarian Cancer Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Ovarian Cancer Drugs Revenue Share by Region (2015-2020)
Table 13. Global Ovarian Cancer Drugs Sales (K Units) Forecast by Region (2021-2026)
Table 14. Global Ovarian Cancer Drugs Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Ovarian Cancer Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Ovarian Cancer Drugs Revenue Share Forecast by Region (2021-2026)
Table 17. Global Ovarian Cancer Drugs (K Units) of Key Companies (2015-2020)
Table 18. Global Ovarian Cancer Drugs Sales Share by Company (2015-2020)
Table 19. Global Ovarian Cancer Drugs Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Ovarian Cancer Drugs Revenue Share by Company (2015-2020)
Table 21. Global Ovarian Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ovarian Cancer Drugs as of 2019)
Table 22. Global Ovarian Cancer Drugs Average Price (USD/Unit) of Key Company (2015-2020)
Table 23. Manufacturers Ovarian Cancer Drugs Manufacturing Sites and Area Served
Table 24. Manufacturers Ovarian Cancer Drugs Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Ovarian Cancer Drugs Players
Table 27. Global Ovarian Cancer Drugs Sales (K Units) by Type (2015-2020)
Table 28. Global Ovarian Cancer Drugs Sales Share by Type (2015-2020)
Table 29. Global Ovarian Cancer Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Ovarian Cancer Drugs Price (K Units) by Type (2015-2020)
Table 31. Global Ovarian Cancer Drugs Sales Share by Type (2021-2026)
Table 32. Global Ovarian Cancer Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Ovarian Cancer Drugs Revenue Share by Type (2021-2026)
Table 34. Global Ovarian Cancer Drugs Price (K Units) by Type (2021-2026)
Table 35. Global Ovarian Cancer Drugs Sales (K Units) by Application (2015-2020)
Table 36. Global Ovarian Cancer Drugs Sales Share by Application (2015-2020)
Table 37. Global Ovarian Cancer Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Ovarian Cancer Drugs Price (K Units) by Application (2015-2020)
Table 39. Global Ovarian Cancer Drugs Sales (K Units) by Application (2021-2026)
Table 40. Global Ovarian Cancer Drugs Sales Share by Application (2021-2026)
Table 41. Global Ovarian Cancer Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Ovarian Cancer Drugs Revenue Share by Application (2021-2026)
Table 43. Global Ovarian Cancer Drugs Price (K Units) by Application (2021-2026)
Table 44. United States Ovarian Cancer Drugs Sales (K Units) by Company (2015-2020)
Table 45. United States Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
Table 46. United States Ovarian Cancer Drugs Sales (K Units) by Type (2015-2020)
Table 47. United States Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
Table 48. United States Ovarian Cancer Drugs Sales (K Units) by Application (2015-2020)
Table 49. United States Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
Table 50. Europe Ovarian Cancer Drugs Sales (K Units) by Company (2015-2020)
Table 51. Europe Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
Table 52. Europe Ovarian Cancer Drugs Sales (K Units) by Type (2015-2020)
Table 53. Europe Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
Table 54. Europe Ovarian Cancer Drugs Sales (K Units) by Application (2015-2020)
Table 55. Europe Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
Table 56. China Ovarian Cancer Drugs Sales (K Units) by Company (2015-2020)
Table 57. China Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
Table 58. China Ovarian Cancer Drugs Sales (K Units) by Type (2015-2020)
Table 59. China Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
Table 60. China Ovarian Cancer Drugs Sales (K Units) by Application (2015-2020)
Table 61. China Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
Table 62. Japan Ovarian Cancer Drugs Sales (K Units) by Company (2015-2020)
Table 63. Japan Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
Table 64. Japan Ovarian Cancer Drugs Sales (K Units) by Type (2015-2020)
Table 65. Japan Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
Table 66. Japan Ovarian Cancer Drugs Sales (K Units) by Application (2015-2020)
Table 67. Japan Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Ovarian Cancer Drugs Sales (K Units) by Company (2015-2020)
Table 69. Southeast Asia Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Ovarian Cancer Drugs Sales (K Units) by Type (2015-2020)
Table 71. Southeast Asia Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Ovarian Cancer Drugs Sales (K Units) by Type (2015-2020)
Table 73. Southeast Asia Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
Table 74. India Ovarian Cancer Drugs Sales (K Units) by Company (2015-2020)
Table 75. India Ovarian Cancer Drugs Sales Market Share by Company (2015-2020)
Table 76. India Ovarian Cancer Drugs Sales (K Units) by Type (2015-2020)
Table 77. India Ovarian Cancer Drugs Sales Market Share by Type (2015-2020)
Table 78. India Ovarian Cancer Drugs Sales (K Units) by Application (2015-2020)
Table 79. India Ovarian Cancer Drugs Sales Market Share by Application (2015-2020)
Table 80. Allergan plc Corporation Information
Table 81. Allergan plc Description and Business Overview
Table 82. Allergan plc Ovarian Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Allergan plc Ovarian Cancer Drugs Product
Table 84. Allergan plc Recent Development
Table 85. Pfizer, Inc. Corporation Information
Table 86. Pfizer, Inc. Description and Business Overview
Table 87. Pfizer, Inc. Ovarian Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Pfizer, Inc. Ovarian Cancer Drugs Product
Table 89. Pfizer, Inc. Recent Development
Table 90. Merck KGaA Corporation Information
Table 91. Merck KGaA Description and Business Overview
Table 92. Merck KGaA Ovarian Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Merck KGaA Ovarian Cancer Drugs Product
Table 94. Merck KGaA Recent Development
Table 95. AstraZeneca Corporation Information
Table 96. AstraZeneca Description and Business Overview
Table 97. AstraZeneca Ovarian Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. AstraZeneca Ovarian Cancer Drugs Product
Table 99. AstraZeneca Recent Development
Table 100. F. Hoffmann-La Roche AG Corporation Information
Table 101. F. Hoffmann-La Roche AG Description and Business Overview
Table 102. F. Hoffmann-La Roche AG Ovarian Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. F. Hoffmann-La Roche AG Ovarian Cancer Drugs Product
Table 104. F. Hoffmann-La Roche AG Recent Development
Table 105. Johnson & Johnson Corporation Information
Table 106. Johnson & Johnson Description and Business Overview
Table 107. Johnson & Johnson Ovarian Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Johnson & Johnson Ovarian Cancer Drugs Product
Table 109. Johnson & Johnson Recent Development
Table 110. Syndax Pharmaceuticals, Inc. Corporation Information
Table 111. Syndax Pharmaceuticals, Inc. Description and Business Overview
Table 112. Syndax Pharmaceuticals, Inc. Ovarian Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. Syndax Pharmaceuticals, Inc. Ovarian Cancer Drugs Product
Table 114. Syndax Pharmaceuticals, Inc. Recent Development
Table . Clovis Oncology Corporation Information
Table . Clovis Oncology Ovarian Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table . Clovis Oncology Description and Business Overview
Table . Clovis Oncology Ovarian Cancer Drugs Product
Table . Clovis Oncology Recent Development
Table 120. Production Base and Market Concentration Rate of Raw Material
Table 121. Key Suppliers of Raw Materials
Table 122. Ovarian Cancer Drugs Distributors List
Table 123. Ovarian Cancer Drugs Customers List
Table 124. Market Key Trends
Table 125. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 126. Key Challenges
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Ovarian Cancer Drugs Product Picture
Figure 2. Global Ovarian Cancer Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Ovarian Cancer Drugs Market Share by Application in 2020 & 2026
Figure 6. Hospital Pharmacies Examples
Figure 7. Drug Stores Examples
Figure 8. Online Pharmacies Examples
Figure 9. Others Examples
Figure 10. Global Ovarian Cancer Drugs Sales (K Units) Growth Rate (2015-2026)
Figure 11. Global Ovarian Cancer Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 12. Global Ovarian Cancer Drugs Price Trends Growth Rate (2015-2026) (USD/Unit)
Figure 13. Global Ovarian Cancer Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 14. Global Ovarian Cancer Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 15. United States Ovarian Cancer Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. United States Ovarian Cancer Drugs Sales (K Units) Growth Rate (2015-2026)
Figure 17. Europe Ovarian Cancer Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. Europe Ovarian Cancer Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 19. China Ovarian Cancer Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. China Ovarian Cancer Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 21. Japan Ovarian Cancer Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Japan Ovarian Cancer Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Ovarian Cancer Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Ovarian Cancer Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 25. India Ovarian Cancer Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 26. India Ovarian Cancer Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 27. Global 5 Largest Ovarian Cancer Drugs Players Market Share by Revenue in Ovarian Cancer Drugs 2015 & 2019
Figure 28. Ovarian Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global Ovarian Cancer Drugs Revenue Share by Type (2015-2020)
Figure 30. Global Ovarian Cancer Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 31. Global Ovarian Cancer Drugs Revenue Share by Application (2015-2020)
Figure 32. Global Ovarian Cancer Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 33. United States Ovarian Cancer Drugs Sales Market Share by Type in 2019
Figure 34. United States Ovarian Cancer Drugs Sales Market Share by Type in 2019
Figure 35. Europe Ovarian Cancer Drugs Sales Market Share by Company in 2019
Figure 36. Europe Ovarian Cancer Drugs Sales Market Share by Type in 2019
Figure 37. Europe Ovarian Cancer Drugs Sales Market Share by Application in 2019
Figure 38. China Ovarian Cancer Drugs Sales Market Share by Company in 2019
Figure 39. China Ovarian Cancer Drugs Sales Market Share by Type in 2019
Figure 40. China Ovarian Cancer Drugs Sales Market Share by Application in 2019
Figure 41. Japan Ovarian Cancer Drugs Sales Market Share by Company in 2019
Figure 42. Japan Ovarian Cancer Drugs Sales Market Share by Type in 2019
Figure 43. Japan Ovarian Cancer Drugs Sales Market Share by Application in 2019
Figure 44. Southeast Asia Ovarian Cancer Drugs Sales Market Share by Company in 2019
Figure 45. Southeast Asia Ovarian Cancer Drugs Sales Market Share by Type in 2019
Figure 46. Southeast Asia Ovarian Cancer Drugs Sales Market Share by Application in 2019
Figure 47. India Ovarian Cancer Drugs Sales Market Share by Company in 2019
Figure 48. India Ovarian Cancer Drugs Sales Market Share by Type in 2019
Figure 49. India Ovarian Cancer Drugs Sales Market Share by Application in 2019
Figure 50. Allergan plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Pfizer, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Merck KGaA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. F. Hoffmann-La Roche AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Syndax Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Clovis Oncology Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Key Raw Materials Price Trend
Figure 59. Manufacturing Cost Structure of Ovarian Cancer Drugs
Figure 60. Manufacturing Process Analysis of Ovarian Cancer Drugs
Figure 61. Ovarian Cancer Drugs Industrial Chain Analysis
Figure 62. Channels of Distribution
Figure 63. Distributors Profiles
Figure 64. Porter's Five Forces Analysis
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
大腸がん治療薬の世界市場レポート2020 A recently published report by QY Research titled Global Colorectal Cancer Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides acc…- 乳がん治療薬の世界市場レポート2020 Breast Cancer Drugs are a type of drugs developed to cure or prevent breast cancer. Market Analysis and Insights: Global Breast Cancer Drugs Market Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization d…
- 胆管がん治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Bile Duct Cancer Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Bile Duct Cancer Drugs…
- 胆管がん治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Bile Duct Cancer Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Bile Duct Cancer Drugs…
- 非小細胞肺がん治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Drugs for Non-small Cell Lung Cancer market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Drugs fo…